Telix Pharmaceuticals joins Thera4Care initiative to develop FAP-targeting therapies

Telix Pharmaceuticals has announced its participation in the Thera4Care project, a European initiative focused on expanding the clinical application of theranostic medicine. The company will utilize its TLX400-Tx candidate, which targets fibroblast activation protein (FAP), as part of the collaboration.

The project aims to evaluate the efficacy of combining FAP-targeting agents with terbium-161, a radioisotope currently being explored for cancer treatment. By integrating this isotope with Telix's targeting molecule, researchers seek to assess improvements in therapeutic outcomes for patients with solid tumors.

This partnership aligns with the broader push in the oncology sector to develop precision medicine alternatives to traditional chemotherapy. The Thera4Care ecosystem provides the infrastructure to accelerate the clinical translation of these radiopharmaceutical candidates across European markets.